Loading...
Loading...
COLL| Name | Value |
|---|---|
| Revenues | 149.7M |
| Cost of Revenue | 55.1M |
| Gross Profit | 94.6M |
| Operating Expense | 32.9M |
| Operating I/L | 61.7M |
| Other Income/Expense | -15.0M |
| Interest Income | 4.3M |
| Pretax | 46.7M |
| Income Tax Expense | 14.8M |
| Net Income/Loss | 31.9M |
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. These products are designed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
